The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s HER2 inhibitors market report forecasts the HER2 inhibitors market size to grow to $11.5 Billion by 2027, with a CAGR (compound annual growth rate) of more than 9%.

Learn More On The HER2 Inhibitors Market Report 2023 – https://www.thebusinessresearchcompany.com/report/her2-inhibitor-global-market-report

HER2 Inhibitors Market Size Forecast

The global HER2 inhibitors market is expected to grow from $7.26 billion in 2022 to $7.98 billion in 2023 at a compound annual growth rate (CAGR) of 9.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The her2 inhibitors market market is expected to grow from $11.5 billion in 2027 at a CAGR of 9.6%.

North America held the largest HER2 inhibitors market share, and Middle East was the fastest-growing region in 2022.

Key HER2 Inhibitors Market Driver ­– Rise In The Number Of Breast Cancer Cases Globally

According to the American Cancer Society, as of January 2020, there were more than 3.5 million women with a history of breast cancer in the US. This includes women who are currently being treated and women who have completed their treatment. According to the World Health Organization (WHO), breast cancer affected 2.3 million women globally in 2020, with 685 000 fatalities. Therefore, the rise in the breast cancer incidence rate globally is anticipated to boost the demand for the HER-2 inhibitors market over the forthcoming years.

Request for A Sample Of The Global HER2 Inhibitors Market Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3396&type=smp

Key HER2 Inhibitors Market Trend – Acquiring Or Partnering With Biopharmaceutical Companies

Biotechnology companies are focusing on acquiring or partnering with biopharmaceutical companies to develop and promote the HER-2 inhibitor market. In recent years, several collaborations have helped these companies expand their HER-2 inhibitor portfolios, increase revenues, and share costs. For instance, in June 2020, Alphamab Oncology, a biotechnology company, collaborated with Sanofi, a pharmaceutical company, to investigate KN026 in combination with other drugs for the treatment of HER2 breast cancer. KN026 is a HER2 inhibitor developed by Alphamab Oncology.

HER2 Inhibitors Market Segment

1) By Treatment: Monotherapy, Combination Therapy

2) By Application: Squamous Cell Carcinoma, Adenocarcinoma, Large Cell Carcinoma, Breast Cancer, Other Applications

3) By End User: Hospitals, Clinics, Other End Users

HER2 Inhibitors Market Major Players and Strategies

Major players in the HER2 inhibitors market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Pfizer Inc., Puma Biotechnology Inc., Boehringer-Ingelheim, Mylan, and Biocon.

In August 2021, Pfizer Inc., a US-based pharmaceutical and biotechnology corporation, acquired Trillium Therapeutics Inc. for an undisclosed amount. This acquisition of Trillium will build a robust record of leadership in oncology, enhancing the haematology portfolio to enhance outcomes for people living with blood cancers worldwide. Trillium Therapeutics Inc is a Canada-based company that develops therapies for the treatment of cancer.

The HER2 Inhibitors Global Market Report 2023 covers regional data on HER2 inhibitors market size, HER2 inhibitors market trends and drivers, opportunities, strategies, and HER2 inhibitors market competitor analysis. The countries covered in the HER2 inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

HER2 inhibitors refer to a group of drugs used to treat certain HER2-low breast malignancies as well as all stages of HER2-positive breast cancer, from early-stage to metastatic. Anti-HER2 drugs bind to the HER2 receptor proteins on the surface of breast cancer cells, and they function by preventing the HER2 receptors in HER2-positive breast cancer from receiving growth impulses.

View More Reports Related To The HER2 Inhibitors Market –

Interleukin Inhibitors Global Market Report 2023

TNF Alpha Inhibitors Global Market Report 2023

Protein Inhibitors Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: